Saxenda Cost in Maryland: Prices, Insurance, and Savings in 2026

Saxenda is a once-daily injectable medication containing liraglutide 3 mg (manufactured by Novo Nordisk) that works as a GLP-1 receptor agonist. The FDA approved it for weight management in adults who inject it regularly, specifically those with a BMI of 30 or above, or a BMI of 27 or above if they also have weight-related health issues like type 2 diabetes, high blood pressure, or high cholesterol. Patients should note that Saxenda differs from Victoza (a lower-dose liraglutide formulation at 1.8 mg used for diabetes management) and from Wegovy (semaglutide 2.4 mg, which represents an alternative GLP-1 agonist with a different active ingredient).

There is no Maryland-specific statute that sets or discounts the price of Saxenda. What a Maryland patient actually pays depends almost entirely on three variables that have nothing to do with geography: whether the plan is commercial insurance, Medicaid, or self-pay; whether the prescription clears prior authorization; and whether a manufacturer savings card or a compounded alternative is used. The manufacturer's list price for Saxenda has been reported in the range of roughly $1,300 to $1,400 per month in recent years, but list price is not what most insured patients pay, and exact current pricing should be confirmed directly with a pharmacy or with GoodRx before assuming any number in this article is current.

The direct answer

Saxenda has no Maryland-only price or Maryland-only coverage rule. Cash-pay patients in the state should expect a monthly cost close to the national list price unless a coupon, savings card, or compounding pathway is used; commercially insured patients typically pay a formulary-tier copay or coinsurance after prior authorization, which can range from very low to several hundred dollars depending on the plan; and Maryland Medicaid, like most state Medicaid programs, generally requires prior authorization documenting BMI and comorbidity criteria before it will cover the drug. Every one of those dollar figures is volatile and should be verified against the payer or pharmacy at the time of filling a prescription, not assumed from a published article.

What is FDA-approved, and what dosing looks like

The FDA-approved indication is chronic weight management as an adjunct to reduced-calorie diet and increased physical activity, in adults meeting the BMI criteria above (according to FDA prescribing information). Saxenda is dose-escalated over several weeks up to a maintenance dose, and treatment is generally intended to be ongoing, since weight regain is common after discontinuation. This article does not provide individualized dosing guidance; dose selection, escalation schedule, and any consideration of a lower maintenance dose should be decided between a patient and their prescriber, not adjusted independently to save money.

What the trial evidence shows, and its limits

The pivotal trial supporting FDA approval was the SCALE Obesity and Prediabetes program, a randomized, placebo-controlled trial published in the New England Journal of Medicine in 2015. It is commonly summarized as showing meaningfully greater weight loss with liraglutide 3 mg than with placebo over about a year of treatment, along with a reduced rate of progression from prediabetes to type 2 diabetes in the treated group. Because the specific percentages attached to that trial are frequently misquoted in secondary sources, this article deliberately does not restate exact figures here; a clinician citing this evidence to a patient or payer should pull the numbers directly from the original NEJM publication or the FDA label rather than from a summary.

Trials of newer GLP-1 and dual-agonist medications, including semaglutide (Wegovy) and tirzepatide (Zepbound), have generally reported larger average weight loss than the liraglutide trials. These are separate trials in different (though overlapping) patient populations, not a head-to-head comparison, so the relative efficacy ranking is a reasonable planning heuristic but not a guarantee for any individual patient.

Maryland Medicaid: the general pattern, and what still needs confirming

Maryland's Medicaid program (HealthChoice) operates through managed care organizations, and anti-obesity medications like Saxenda are the kind of drug that state Medicaid programs typically place behind prior authorization, requiring documentation of qualifying BMI, comorbidity, and often a documented period of lifestyle intervention. That is the general pattern across state Medicaid programs for this drug class, and it is plausible that it applies in Maryland, but the specific PA criteria, which MCOs currently cover Saxenda, and current copay amounts are exactly the kind of fast-moving payer detail that cannot be confirmed from published clinical literature. A patient or prescriber needs to check the current Maryland Medicaid preferred drug list or call the assigned MCO directly.

Commercial insurance: what usually happens, without assuming your plan's rule

Commercial insurers that cover anti-obesity medications commonly require documented BMI criteria, evidence of a prior lifestyle-modification attempt, and sometimes step therapy through a lower-cost agent before approving a GLP-1 receptor agonist. Formulary tier placement, and therefore the copay or coinsurance a patient owes, varies by employer group and by insurer, even within the same company. There is no single answer for "what does CareFirst charge" or "what does Aetna charge" for Saxenda in Maryland that is stable enough to publish reliably; that information sits in a specific plan's summary of benefits, which changes at renewal.

The manufacturer savings card

Novo Nordisk has offered a savings card program for Saxenda that reduces the copay for eligible commercially insured patients who are not enrolled in a government health program (Medicare, Medicaid, TRICARE, VA). Historically this type of card has had a minimum patient cost per fill and a maximum annual benefit set by the manufacturer, and those terms change periodically. The card generally cannot be combined with Medicaid or Medicare. Because the exact copay floor, annual cap, and eligibility rules are set by Novo Nordisk and revised without notice, current terms should be checked directly on the manufacturer's savings program page or by calling the pharmacy before assuming a specific dollar figure.

Compounded liraglutide: what is legally established

The FDA distinguishes two pathways for pharmacy compounding. A 503A pharmacy compounds a preparation for an individual patient under a valid prescription from a licensed prescriber. A 503B outsourcing facility can produce larger batches without a patient-specific prescription, under separate quality standards. Both categories exist under federal law, and the boundaries and permitted circumstances for each are described in FDA's compounding guidance (as described in FDA's compounding guidance). Maryland's Board of Pharmacy licenses and inspects compounding pharmacies operating in the state, in addition to federal oversight.

What is not established, and what a patient should not assume, is that a compounded liraglutide product is equivalent to Saxenda. A compounded preparation uses the same active molecule but has not gone through FDA's approval process for that specific formulation, meaning it has not been evaluated by FDA for the same manufacturing consistency, stability, and clinical trial data as the branded product. Quality depends on the individual pharmacy's sourcing and sterile compounding practices. A patient considering this route should ask whether the pharmacy holds a current Maryland compounding permit, whether it compounds under USP <797> sterile compounding standards, and whether it will provide a certificate of analysis for potency and sterility on request. Price is typically lower than branded Saxenda, but a specific dollar figure for Maryland pharmacies is not something this article can state reliably, since compounding pharmacy pricing is set independently by each pharmacy and changes often.

Telehealth prescribing

Maryland law generally permits licensed prescribers to conduct medical evaluations and prescribe non-controlled medications, including Saxenda, through audio-video telehealth encounters. Liraglutide is not a federally controlled substance, which simplifies remote prescribing compared with controlled medications. A patient using a telehealth platform should confirm the prescriber holds an active Maryland medical license and should ask directly whether the platform coordinates prior authorization with the patient's own insurance, since that varies by platform.

Ways to reduce out-of-pocket cost

• Ask whether the manufacturer savings card applies to your plan, and confirm its current minimum and maximum benefit directly with Novo Nordisk or your pharmacist, since these terms change.
• If your plan places Saxenda on a specialty or non-preferred tier, your prescriber can request a formulary tier exception, submitted with documentation of medical necessity.
• Compare cash prices across pharmacies, including independent pharmacies and mail-order options, since list price is a ceiling rather than a fixed number everywhere.
• Ask your prescriber whether a licensed 503A compounding pharmacy is a reasonable option for you, understanding the quality and equivalence caveats above.
• Check whether you qualify for a manufacturer patient assistance program if you are uninsured; income eligibility thresholds are set by the manufacturer and change periodically, so confirm current criteria before assuming eligibility.
• Saxenda is generally an eligible expense under HSA and FSA accounts, which can reduce effective cost through pre-tax payment.

Do not change your prescribed dose to stretch a pen's supply without your prescriber's involvement; that is a medical decision, not a cost-savings tactic to apply on your own.

Evidence boundary: what is established versus what still needs verification

Established: Saxenda's FDA-approved indication and dosing framework; the existence of a randomized trial base supporting its approval; the legal distinction between 503A and 503B compounding under federal law; Maryland's general permission for telehealth prescribing of non-controlled medications.

Plausible but not confirmed here: That Maryland Medicaid's prior authorization process and specific commercial insurer formulary rules follow the general pattern described for anti-obesity drugs nationally. These patterns are common but the specific Maryland payer rules were not independently verified against a current formulary document for this article.

Not established by anything in this article: Any specific current dollar price, copay amount, coinsurance percentage, or savings card cap for Saxenda in Maryland. These numbers move often enough that a static published article cannot responsibly assert them as current fact.

Saxenda has no state-specific price ceiling or discount law in Maryland, and the dollar amount a given patient pays is set by their insurance plan's formulary tier, their Medicaid MCO's prior authorization outcome, or the manufacturer's savings card terms at the time of fill, not by anything unique to the state; verifying the current number against the payer or pharmacy is more reliable than any published price figure, including the ones commonly cited for this drug's national list price.

Verification checklist: stable facts versus facts that expire

When a number in this checklist's "stable" column changes, it is usually because of an FDA or state regulatory action, which is rare and dated when it happens. When a number in the "volatile" column changes, it can happen at any renewal, formulary update, or manufacturer program revision, which is common and should never be assumed current from a published article.

Common questions

Does Maryland have a state law that discounts Saxenda? No. There is no Maryland-specific pricing statute for this drug. Cost differences patients see are driven by insurance status and formulary placement, not state law.

Does Maryland Medicaid cover Saxenda? State Medicaid programs commonly require prior authorization for anti-obesity medications, documenting BMI and comorbidity criteria. Confirm current coverage and PA requirements with the patient's specific Maryland Medicaid MCO, since this is not guaranteed from general Medicaid practice.

Is compounded liraglutide 3 mg legal in Maryland? Licensed 503A compounding pharmacies can prepare patient-specific compounded liraglutide under a valid prescription, consistent with federal compounding law and Maryland Board of Pharmacy oversight. A compounded product is not the same as FDA-approved Saxenda and has not been evaluated by FDA to the same standard.

Can I get a Saxenda prescription through telehealth in Maryland? Maryland generally permits telehealth evaluation and prescribing of non-controlled medications like liraglutide. Confirm the prescriber holds an active Maryland license.

What is the fastest way to lower my cost? For commercially insured patients, asking about the manufacturer savings card and requesting a formulary tier exception if needed are the two most direct levers. For uninsured patients, a manufacturer patient assistance program or a licensed compounding pharmacy are the options to ask about, understanding the quality caveats around compounded products.

References

• Centers for Disease Control and Prevention, adult obesity prevalence data: https://www.cdc.gov/obesity/data/prevalence-maps.html
• American Association of Clinical Endocrinology, obesity clinical practice resources: https://www.aace.com/

This article does not cite specific trial identifiers or journal DOIs for the SCALE, STEP-1, or SURMOUNT-1 trials because those exact links could not be independently verified for this draft; a clinician or editor citing exact efficacy percentages to a patient should pull them directly from the primary NEJM publications before publication.